



# Enhertu in the UAE

*The MoHAP named-patient coordination pathway — indicative 2026*

ONCOLOGY · HER2 BREAST / GASTRIC / NSCLC

## The clinical situation

Enhertu (trastuzumab deruxtecan, T-DXd) is an FDA-approved antibody-drug conjugate coupling a HER2-targeted antibody with a topoisomerase I inhibitor payload. Given as an intravenous infusion every three weeks in an outpatient oncology setting, it is indicated for HER2-positive and HER2-low metastatic breast cancer, HER2-positive gastric cancer, and HER2-mutant NSCLC. Developed by AstraZeneca and Daiichi Sankyo. Interstitial lung disease surveillance is a standard component of on-treatment monitoring.

### The pathway, 5 steps

- 1 Consultation & clinical rationale.** Your treating oncologist confirms HER2 status (IHC / ISH), line history, and documents a written clinical rationale.
- 2 Infusion facility confirmed.** An outpatient oncology day-unit or infusion suite with cold-chain storage is identified in UAE / Abu Dhabi / Dubai.
- 3 MoHAP named-patient application.** Hospital pharmacy files with MoHAP (or DoH Abu Dhabi / DHA Dubai), including ILD surveillance plan.
- 4 US-side sourcing & logistics.** Reserve Meds coordinates product through our US-licensed DSCSA-compliant specialty wholesale partner; cold-chain shipment with continuous temperature monitoring.
- 5 Arrival & first infusion.** The hospital pharmacy receives product and releases doses on your cycle schedule; subsequent cycles ship on a rolling basis against your calendar.

### Indicative economics

**Reference US cash-pay range:** USD 14,000–20,000 per cycle (driven by weight-based dosing); full multi-cycle course runs substantially more. Cold-chain logistics and concierge coordination incremental. Full transparent quote at intake.

### Indicative first-dose timing

**10–21 days** from a complete MoHAP application to first infusion, once cohort intake opens. Indicative — not guaranteed.

## Reserve Meds's role

**Sourcing.** US-licensed specialty wholesale partner, DSCSA chain-of-custody. **Documentation.** Regulatory package for your physician and MoHAP review. **Logistics.** Cold-chain, temperature-monitored shipment coordination. **Concierge case lead.** Named point of contact for family and physician through intake and cycle-to-cycle refills. **We are a coordinator** — not the prescriber, not the dispensing pharmacy. All clinical decisions remain with your treating oncologist.

**COMPOSITE EXAMPLE · PRE-LAUNCH WAITLIST**

**Join the Enhertu × UAE first-cohort waitlist.** *Our concierge reaches out as we open intake.*

[reservemed.com/access-guides/enhertu-uae.html](https://reservemed.com/access-guides/enhertu-uae.html)



SCAN TO JOIN

**Reserve Meds** · US-based concierge for cross-border specialty medicine. We are a coordinator; we are not the prescriber and not the dispensing pharmacy. All clinical decisions remain with the treating physician. Not medical advice.

*Reserve Meds is in pre-launch. Service availability is limited to our first cohort; all timelines published are indicative, not guarantees. Composite case examples only.*

**reservemed.com** · [hello@reservemed.com](mailto:hello@reservemed.com) · WhatsApp concierge: +1 516 528 3120 · Reviewed 2026-04-23 by Reserve Meds clinical & regulatory team